Ke Z - Search Results

1

Risk factors of breast intraductal lesions in patients without pathological nipple discharge.

Shen L, Ye Y, Liu X, Li W, Wei J, Ke Z, Yang S, Yang Z. Shen L, et al. Among authors: ke z. Mol Clin Oncol. 2020 Oct;13(4):38. doi: 10.3892/mco.2020.2108. Epub 2020 Aug 10. Mol Clin Oncol. 2020. PMID: 32832081 Free PMC article.

2

Rab22a is a novel prognostic marker for cell progression in breast cancer.

He M, Shen L, Jiang C, Gao G, Wang K, Jiao Y, Sun L, Cui Y, Ke Z, Yang Z. He M, et al. Among authors: ke z. Int J Mol Med. 2020 Apr;45(4):1037-1046. doi: 10.3892/ijmm.2020.4486. Epub 2020 Feb 5. Int J Mol Med. 2020. PMID: 32124943 Free PMC article. Clinical Trial.

3

[Corrigendum] Rab22a is a novel prognostic marker for cell progression in breast cancer.

He M, Shen L, Jiang C, Gao G, Wang K, Jiao Y, Sun L, Cui Y, Ke Z, Yang Z. He M, et al. Among authors: ke z. Int J Mol Med. 2021 Mar;47(3):18. doi: 10.3892/ijmm.2021.4851. Epub 2021 Jan 11. Int J Mol Med. 2021. PMID: 33655335 Free PMC article.

4

Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer.

Fan S, Yang Z, Ke Z, Huang K, Liu N, Fang X, Wang K. Fan S, et al. Among authors: ke z. Biomed Pharmacother. 2017 Nov;95:1636-1643. doi: 10.1016/j.biopha.2017.09.076. Epub 2017 Oct 6. Biomed Pharmacother. 2017. PMID: 28950664

5

Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy.

Hou N, Wu J, Xiao J, Wang Z, Song Z, Ke Z, Wang R, Wei M, Xu M, Wei J, Qian X, Xu X, Yi J, Wang T, Zhang J, Li N, Fan J, Hou G, Wang Y, Wang Z, Ling R. Hou N, et al. Among authors: ke z. ESMO Open. 2021 Oct;6(5):100269. doi: 10.1016/j.esmoop.2021.100269. Epub 2021 Sep 16. ESMO Open. 2021. PMID: 34537675 Free PMC article. Clinical Trial.

6

Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients.

Ke ZR, Chen W, Li MX, Wu S, Jin LT, Wang TJ. Ke ZR, et al. World J Clin Cases. 2022 Apr 16;10(11):3389-3400. doi: 10.12998/wjcc.v10.i11.3389. World J Clin Cases. 2022. PMID: 35611192 Free PMC article.

7

Catalyst-Free Activation and Fixation of Nitrogen by Laser-Induced Conversion.

Cao W, Li Y, Yan B, Zeng Z, Liu P, Li R, Jiang J, Ke Z, Yang G. Cao W, et al. Among authors: ke z. J Am Chem Soc. 2024 May 16. doi: 10.1021/jacs.4c02631. Online ahead of print. J Am Chem Soc. 2024. PMID: 38752294

8

The Mechanism of Guerbet Reaction by Metal Ligand Cooperation.

Chen R, Zhou X, Yang F, Zhao C, Ke Z. Chen R, et al. Among authors: ke z. Chemistry. 2024 May 15:e202303861. doi: 10.1002/chem.202303861. Online ahead of print. Chemistry. 2024. PMID: 38751155

9

A faster killing effect of plastid-mediated RNA interference on a leaf beetle through induced dysbiosis of the gut bacteria.

Zhang Y, Ke Z, Xu L, Yang Y, Chang L, Zhang J. Zhang Y, et al. Among authors: ke z. Plant Commun. 2024 May 14:100974. doi: 10.1016/j.xplc.2024.100974. Online ahead of print. Plant Commun. 2024. PMID: 38751119 Free article.

10

Formulation design and characterization of silymarin liposomes for enhanced antitumor activity.

Ke Z, Cheng X, Yang H, Niu Y, Cheng X, Ye T, Sun G, Cheng Z, Sun Y. Ke Z, et al. Pak J Pharm Sci. 2024 Jan;37(1):139-145. Pak J Pharm Sci. 2024. PMID: 38741410

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,278 results

Search Page